ACRS (Aclaris Therapeutics) Total Liabilities: $55.07 Mil (As of Mar. 2026)

What is Aclaris Therapeutics Total Liabilities?

Aclaris Therapeutics ACRS +0.40% 38 Total Liabilities is $55.07 Mil as of Mar. 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Aclaris Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $55.07 Mil.

Aclaris Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($55.43 Mil) to Dec. 2025 ($57.38 Mil) but then declined from Dec. 2025 ($57.38 Mil) to Mar. 2026 ($55.07 Mil).

Aclaris Therapeutics's annual Total Liabilities increased from Dec. 2023 ($40.23 Mil) to Dec. 2024 ($64.77 Mil) but then declined from Dec. 2024 ($64.77 Mil) to Dec. 2025 ($57.38 Mil).

Aclaris Therapeutics Total Liabilities Related Terms

Aclaris Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Total Liabilities Chart

Aclaris Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

53.87

56.98

40.23

64.77

57.38

Aclaris Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															54.03	57.41	55.43	57.38	55.07

38GF Score

Aclaris Therapeutics Inc ACRS

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aclaris Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aclaris Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28.645	+	(0	+	12.565
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	16.168	+	0	+	0)
	=	57.38

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	160.46	-	103.082
	=	57.38

Aclaris Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27.37	+	(0	+	12.416
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	15.285	+	0	+	0)
	=	55.07

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	198.72	-	143.649
	=	55.07

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $55.07 Mil mean?

Aclaris Therapeutics (ACRS) has a Total Liabilities of $55.07 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aclaris Therapeutics and its competitors.

Is Aclaris Therapeutics' Total Liabilities too high?

Aclaris Therapeutics' current Total Liabilities is $55.07 Mil. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aclaris Therapeutics' Total Liabilities compare to RLMD and GYRE?

Aclaris Therapeutics' Total Liabilities of $55.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Total Liabilities is $55.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aclaris Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.04 — trading 1018.9% above its estimated fair value. The current Total Liabilities is $55.07 Mil. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Total Liabilities is $55.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.04 is trading 1018.9% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

Total Liabilities: $55.07 Mil
GF Value™: $0.45 vs. price of $5.04 (1018.9% above fair value)
GF Score™: 38/100 with 10 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies RLMD GYRE SGP IMMX RIGL AGMB CADL AURA NVCT OCS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0H8T:UK 8AT:Germany

Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087

Website https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

38GF Score

Get the complete analysis for ACRS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.04

Price

$0.45

GF Value

View ACRS Analysis

See Total Liabilities data for all stocks →